Evofem Biosciences, Inc.EVFMOTCMARKET
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank75
3Y CAGR-2.7%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
-2.7%/yr
vs +21.4%/yr prior
Acceleration
-24.1pp
Decelerating
Percentile
P75
Within normal range
vs 3Y Ago
0.9x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 21.50% |
| Q2 2025 | -482.57% |
| Q1 2025 | 132.60% |
| Q4 2024 | 58.89% |
| Q3 2024 | -75.67% |
| Q2 2024 | 51.16% |
| Q1 2024 | 15.86% |
| Q4 2023 | 4.84% |
| Q3 2023 | 51.58% |
| Q2 2023 | -104.97% |
| Q1 2023 | 69.28% |
| Q4 2022 | 37.77% |
| Q3 2022 | 23.32% |
| Q2 2022 | 15.59% |
| Q1 2022 | 22.69% |
| Q4 2021 | 13.72% |
| Q3 2021 | -5.41% |
| Q2 2021 | 8.31% |
| Q1 2021 | -25.16% |
| Q4 2020 | -37.07% |
| Q3 2020 | -16.91% |
| Q2 2020 | -16.25% |
| Q1 2020 | -49.50% |
| Q4 2019 | 9.97% |
| Q3 2019 | -19.73% |
| Q2 2019 | 12.40% |
| Q1 2019 | 9.00% |
| Q4 2018 | 18.73% |
| Q3 2018 | 20.69% |
| Q2 2018 | -10.75% |
| Q1 2018 | -785.13% |
| Q4 2017 | -30.29% |
| Q3 2017 | 35.65% |
| Q2 2017 | 6.55% |
| Q1 2017 | -52.72% |
| Q4 2016 | -5.95% |
| Q3 2016 | 0.00% |